NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Phlox Therapeutics

Phlox Therapeutics

Private
NaardenHealthcare & Life Scienceshttps://phloxtherapeutics.com/

Last Round

Seed

Nov 6, 2024

Total Funding Raised

$2.03M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Phlox Therapeutics is a biotechnology company that develops first-in-class RNA therapies for rare genetic cardiomyopathies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

gene therapyRNA therapeuticscardiomyopathylaminopathygenetic medicineprecision medicineheart failure treatmentbiotech startuppreclinical researchdrug discoveryrare disease therapygenetic heart diseasebiotech R&Dgenomics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phlox Therapeutics Comparables

Compare Phlox Therapeutics with similar companies based on industry and business-model similarity.

Phlox Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nuevocor
81%
Bayer AG
73%
BioMarin Pharmaceutical Inc.
73%

Phlox Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 6, 2024
SeedMay 9, 2023
Pre SeedMay 16, 2022

Key People

Founding team and executive leadership

Margien Boels

Chief Operating Officer

Executive Team

Phlox Therapeutics Investors

Notable investors and investment history

Phlox Therapeutics investors
InvestorRounds
ROM Utrecht RegionSeed
Amsterdam UMC Ventures HoldingSeed
Innovation Fund Noord-HollandSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 14, 2026

    Monthly visitors grew 71% MoM, reaching 1.2K.

  • Apr 6, 2026

    Monthly visitors increased 171% MoM, from 143 to 388.

Phlox Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Phlox Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Phlox Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNaarden
Employee Range8
Year Founded2022
Last FundingNov 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.